Elicio Therapeutics reports Q1 2024 net loss of $11.8M; provides clinical updates for ELI-002

Elicio Therapeutics, Inc.

2024-Q1 EPS reported -$1.15

Net loss $11.8M ($1.15 per share) vs $8.0M in Q1 2023; R&D expense increased to $7.6M from $5.5M.
Cash and equivalents $11.9M as of March 31, 2024, down from $12.9M at December 31, 2023.
ELI-002 2P Phase 1 data published in Nature Medicine; ELI-002 7P Phase 1 preliminary data at ASCO in June 2024.
Randomized Phase 2 trial of ELI-002 7P enrollment expected to complete in Q4 2024; interim analysis in Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Elicio Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $11.8 million, EPS $1.15.

Period: the first quarter ended March 31, 2024
Net income: $11.8 million
EPS: $1.15
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $11.8 million, compared to $8.0 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $1.15 compared to $24.77 for the first quarter of 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.